Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Heparin binds to antithrombin III, causing a conformational change that accelerates the inactivation of factor Xa and thrombin, thereby inhibiting coagulation.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Prophylaxis and treatment of venous thromboembolism,Atrial fibrillation with embolization,Treatment of acute coronary syndromes (e.g., unstable angina, NSTEMI),Maintenance of patency of intravenous catheters,Off-label: Treatment of disseminated intravascular coagulation
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
For venous thromboembolism prophylaxis: 5000 units subcutaneously every 8-12 hours. For therapeutic anticoagulation: weight-based IV bolus (60-80 units/kg) followed by continuous IV infusion (12-18 units/kg/hour) adjusted to target a PTT. 1.5-2.5 times control.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
The terminal elimination half-life of heparin is dose-dependent, ranging from 0.5 to 2 hours for intravenous doses of 100-400 U/kg. At higher doses, half-life may extend to 2.5 hours. Clinical context: linear pharmacokinetics; half-life increases with dose due to saturable clearance mechanisms (reticuloendothelial uptake and hepatic metabolism).
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Primarily cleared via reticuloendothelial system and desulfation; partially metabolized by heparinase; renal excretion of metabolites.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
Heparin is primarily eliminated via the reticuloendothelial system and metabolized in the liver. Renal excretion of unchanged heparin is minimal (<5%) at therapeutic doses. Biliary/fecal excretion is negligible.
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
Heparin is extensively bound to antithrombin III (AT-III) with high affinity. It also binds to other plasma proteins including platelet factor 4, histidine-rich glycoprotein, and fibrinogen. Nonspecific binding to albumin occurs but is low affinity; overall binding is not expressed as a simple percentage due to complex binding interactions.
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
Volume of distribution is approximately 0.05-0.1 L/kg (5-10% body weight), confined largely to the plasma volume. Clinical meaning: heparin does not distribute to extravascular tissues; its Vd approximates blood volume.
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
Subcutaneous: bioavailability is 20-30% due to poor absorption; intravenous: 100%.
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
No specific dose adjustment required based on GFR; however, heparin is primarily cleared by the liver and reticuloendothelial system, and renal impairment does not significantly alter pharmacokinetics. Use with caution in severe renal impairment due to increased bleeding risk.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
No formal Child-Pugh based dosing adjustments. Hepatic impairment may prolong heparin's half-life; consider reducing initial bolus and infusion rates, monitor a PTT closely.
No dosage adjustment required for hepatic impairment.
For prophylaxis: 50-100 units/kg subcutaneously every 12 hours. For therapeutic anticoagulation: initial bolus 75-100 units/kg IV over 10 minutes; maintenance infusion: age-based: infants <1 year: 28 units/kg/hour; children >1 year: 20 units/kg/hour; adolescents: 18 units/kg/hour. Titrate to target a PTT.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Elderly patients may have altered pharmacokinetics and increased bleeding risk. Initial dosing should be based on actual body weight; consider lower initial infusion rates (e.g., 10-15 units/kg/hour) with close monitoring of a PTT and signs of bleeding.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
Spinal/epidural hematomas may occur in patients receiving anticoagulants, including heparin, who are undergoing neuraxial anesthesia or spinal puncture, resulting in long-term or permanent paralysis.
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
Risk of hemorrhage: monitor for bleeding, especially at invasive procedure sites. Heparin-induced thrombocytopenia (HIT): monitor platelet counts. Hypersensitivity reactions. Elevated hepatic enzymes. Osteoporosis with prolonged use.
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Hypersensitivity to heparin or pork products. Active major bleeding. History of heparin-induced thrombocytopenia. Severe thrombocytopenia. Uncontrolled bleeding disorders.
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
No specific food interactions. Avoid excessive alcohol intake due to increased bleeding risk.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
Heparin does not cross the placenta and is not associated with fetal teratogenicity in any trimester. No increased risk of congenital anomalies has been reported. However, maternal use may cause bleeding complications affecting pregnancy outcomes.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Heparin is not excreted into breast milk due to its large molecular weight and ionic charge. The American Academy of Pediatrics considers heparin compatible with breastfeeding. M/P ratio is not applicable as drug is not detected in milk.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
No routine dose adjustment required based solely on pregnancy. Monitor a PTT closely due to pregnancy-related increased plasma volume and clearance; dose may need to be increased to maintain therapeutic a PTT. Postpartum, dose may need reduction as plasma volume normalizes.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
Monitor activated partial thromboplastin time (a PTT) 6 hours after initiation and after each dose adjustment. Use 0.9% sodium chloride as flush to maintain patency of heparin lock. Avoid intramuscular injections during therapy due to risk of hematoma. Protamine sulfate is the reversal agent (1 mg neutralizes 100 units of heparin).
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
Report any unusual bleeding, bruising, or dark stools.,Use an electric razor and soft toothbrush to minimize bleeding risk.,Avoid activities that may cause injury or falls.,Inform all healthcare providers that you are taking heparin.,Do not take any new medications, including over-the-counter drugs, without consulting your doctor.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Heparin binds to antithrombin III, causing a conformational change that accelerates the inactivation of factor Xa and thrombin, thereby inhibiting coagulation.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: For venous thromboembolism prophylaxis: 5000 units subcutaneously every 8-12 hours. For therapeutic anticoagulation: weight-based IV bolus (60-80 units/kg) followed by continuous IV infusion (12-18 units/kg/hour) adjusted to target a PTT. 1.5-2.5 times control.. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Heparin does not cross the placenta and is not associated with fetal teratogenicity in any trimester. No increased risk of congenital anomalies has been reported. However, maternal. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.